Surisham Dhillon
Newhall, CANPI 1770652299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,288 and has fallen 97.7% since, to $30 in 2024.
Across 155 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$571
- Supernus Pharmaceuticals, Inc.$235
- UCB, Inc.$192
- Sanofi$158
- Avanir Pharmaceuticals, Inc.$126
- Livanova USA, Inc.$116
- plus $1K from 24 others
Across 36 payments — averaging $2815.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$37K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$26K
- Pfizer$19K
- Eli Lilly$15K
- Janssen Research & Development, LLC$5K
What the payments were for
- Food & beverage$2,608100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $571 |
| Supernus Pharmaceuticals, Inc. | 28 | $235 |
| UCB, Inc. | 10 | $192 |
| Sanofi | 12 | $158 |
| Avanir Pharmaceuticals, Inc. | 11 | $126 |
| Livanova USA, Inc. | 6 | $116 |
| Amgen | 6 | $114 |
| Genentech USA, Inc. | 6 | $106 |
| EMD Serono, Inc. | 4 | $95 |
| Assertio Therapeutics, Inc. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Greenwich Biosciences, Inc. | 2 | $72 |
| Lilly USA, LLC | 3 | $67 |
| Kyowa Kirin, Inc. | 3 | $65 |
| Argenx US, Inc. | 2 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Biogen | 3 | $49 |
| AstraZeneca | 3 | $43 |
| Akcea Therapeutics, Inc. | 2 | $43 |
| Adamas Pharmaceuticals, Inc. | 2 | $41 |
| Merz North America, Inc. | 1 | $39 |
| Amneal Pharmaceuticals LLC | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Novartis | 1 | $25 |
| Zyla Life Sciences, Inc. | 2 | $25 |
| Acadia Pharmaceuticals Inc | 2 | $23 |
| Eisai Inc. | 1 | $23 |
| GSK | 1 | $19 |
| CSL Behring | 1 | $18 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.